肼屈嗪相关血管炎:药物诱导性狼疮与血管炎的重叠特征
该回顾性研究在323例ANCA相关血管炎患者中识别出12例肼屈嗪暴露者,均表现为ANA与ANCA双阳性、组蛋白及MPO抗体阳性,并伴间质性肺病、低补体血症及寡免疫复合物新月体肾小球肾炎。作者认为肼屈嗪相关血管炎是兼具药物诱导性狼疮与药物诱导性血管炎要素的药物相关自身免疫综合征。
要点
- 肼屈嗪相关血管炎可同时出现药物诱导性狼疮与血管炎的重叠特征。
- 12例患者均ANA与ANCA双阳性,均组蛋白抗体阳性,11例MPO抗体阳性。
- 6例肾活检均示寡免疫复合物新月体肾小球肾炎。
核心结论
- 肼屈嗪相关血管炎是一种药物相关自身免疫综合征,表现为间质性肺病、低补体血症和寡免疫复合物肾小球肾炎。
- 患者兼具药物诱导性狼疮与药物诱导性血管炎要素,表现为高滴度ANA和ANCA以及组蛋白和MPO抗体阳性。
- 原文结论提出需进一步研究以理解该病的病因发病机制。
研究设计与样本
- 回顾性研究,经爱荷华大学机构审查委员会批准。
- 识别过去15年内携带血管炎诊断(ICD9编码447.6或ICD10编码I77.6、I80、L95、M30或M31)且ANCA实验室结果阳性的所有患者。
- 从电子病历中提取年龄、性别、合并症、既往6个月用药、实验室数据(包括电解质、尿液检查和血清学)、胸部X线、CT扫描及病理活检记录。
主要发现
- 共识别323例ANCA相关血管炎,其中12例暴露于肼屈嗪,且均在诊断时暴露。
- 肼屈嗪平均治疗时长22个月,平均累积剂量146g。
- 患者年龄偏大(70.3岁),女性略多(7例女性)。
- 11例表现为呼吸困难、乏力及非意愿性体重下降,5例有多关节痛,8例有下肢瘀点。
- 12例均ANA和ANCA阳性;ANA滴度范围1:160至1:2560,10例为弥漫型、2例为核仁型;ANCA滴度范围1:320至1:2560,11例为pANCA型、1例为cANCA型。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文结论提出需进一步研究以理解该病的病因发病机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hydralazine is an antihypertensive medication that has been associated with drug-induced lupus erythematosus (DIL) as well as ANCA-associated vasculitis (AAV). Although rare, early diagnosis is critical since drug cessation is the mainstay of therapy. This retrospective study aims to characterize the clinical, laboratory, and histopathologic features of this disease. METHODS: Once approval was obtained from the Institutional Review Board at the University of Iowa, all patients carrying a diagnosis of vasculitis (ICD9 code: 447.6 or ICD10 code: I77.6, I80, L95, M30, or M31) and positive ANCA lab results over the past 15 years were identified. Age, gender, comorbid conditions, medications taken over the prior 6 months, laboratory data, including electrolytes, urine studies and serologies, chest x-rays, CT scans, and pathologic biopsy records were abstracted from the electronic medical record. RESULTS: 323 cases of AAV were identified, of which 12 were exposed to hydralazine, all at the time of diagnosis. The average duration of hydralazine therapy was 22 months and mean cumulative dose was 146g. Patients were typically older (70.3 years old) with slight female preponderance (7 females). Eleven patients presented with dyspnea, fatigue, and unintentional weight loss. Five had polyarthralgias and 8 had lower extremity petechiae. All 12 patients were both ANA and ANCA positive. ANA titers ranged from 1:160 and 1:2560. Ten were of diffuse pattern while 2 were nucleolar. ANCA titers ranged from 1:320 to 1:2560. Eleven had a pANCA pattern while one had cANCA. All 12 patients were positive for histone and 11 were positive for myeloperoxidase antibodies. Eleven also had dsDNA antibodies, and 4 had anti-cardiolipin IgG or IgM antibodies. Nine patients were also hypocomplementemic (mean C3 level: 88.4mg/dL; mean C4 level: 16.5mg/dL). All patients had variable levels of proteinuria (1+ to 3+) and eleven had active urine sediment. Urine protein:creatinine ratios ranged from 0.2 to 1.7. Of the 6 patients who underwent kidney biopsy, all 6 showed pauci-immune crescentic glomerulonephritis. Seven patients had bilateral pulmonary interstitial infiltrates and four had pleural effusions on CT scan. Four had pericardial effusions as demonstrated by echocardiography. CONCLUSIONS: Hydralazine-associated vasculitis is a drug-associated autoimmune syndrome that presents with interstitial lung disease, hypocomplementemia, and pauci-immune glomerulonephritis. Patients have elements of both DIL and DIV, as manifested by high ANA and ANCA titers as well as the presence of histone and MPO antibodies. Further research is needed to understand the etiopathogenesis of this condition.
引用
- Kumar B, Strouse J, Swee M, et al. Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018. PMID: 29519741. doi:10.1016/j.semarthrit.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。